EU/3/19/2217

Table of contents

About

On 17 October 2019, orphan designation EU/3/19/2217 was granted by the European Commission to Recordati Rare Diseases, France, for propranolol hydrochloride for the treatment of retinopathy of prematurity.

Key facts

Active substance
propranolol hydrochloride
Disease / condition
Treatment of retinopathy of prematurity
Date of first decision
17/10/2019
Outcome
Positive
EU designation number
EU/3/19/2217

Sponsor's contact details

Recordati Rare Diseases   
Immeuble Le Wilson
70 Avenue Du General De Gaulle
92800 Puteaux
France
Tel. +33 1 4773 9527
E-mail: RRDinfo@recordati.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating